Aliases for RPS6KB1 Gene
- Ribosomal Protein S6 Kinase, 70kDa, Polypeptide 1 2 3
- S6K1 3 4 6
- Serine/Threonine-Protein Kinase 14A 3 4
- Ribosomal Protein S6 Kinase I 3 4
- EC 184.108.40.206 4 63
- S6K-Beta-1 3 4
- P70 S6KA 3 4
- STK14A 3 4
- Ribosomal Protein S6 Kinase, 70kD, Polypeptide 1 2
- 70 KDa Ribosomal Protein S6 Kinase 1 4
- Ribosomal Protein S6 Kinase Beta-1 3
- Serine/Threonine Kinase 14 Alpha 3
- P70 Ribosomal S6 Kinase Alpha 4
External Ids for RPS6KB1 Gene
Previous HGNC Symbols for RPS6KB1 Gene
Previous GeneCards Identifiers for RPS6KB1 Gene
This gene encodes a member of the ribosomal S6 kinase family of serine/threonine kinases. The encoded protein responds to mTOR (mammalian target of rapamycin) signaling to promote protein synthesis, cell growth, and cell proliferation. Activity of this gene has been associated with human cancer. Alternatively spliced transcript variants have been observed. The use of alternative translation start sites results in isoforms with longer or shorter N-termini which may differ in their subcellular localizations. There are two pseudogenes for this gene on chromosome 17. [provided by RefSeq, Jan 2013]
GeneCards Summary for RPS6KB1 Gene
RPS6KB1 (Ribosomal Protein S6 Kinase, 70kDa, Polypeptide 1) is a Protein Coding gene. Diseases associated with RPS6KB1 include tuberous sclerosis and muscle hypertrophy. Among its related pathways are PI3K-Akt signaling pathway and Signaling by GPCR. GO annotations related to this gene include protein kinase activity and ribosomal protein S6 kinase activity. An important paralog of this gene is AKT1.
UniProtKB/Swiss-Prot for RPS6KB1 Gene
Serine/threonine-protein kinase that acts downstream of mTOR signaling in response to growth factors and nutrients to promote cell proliferation, cell growth and cell cycle progression. Regulates protein synthesis through phosphorylation of EIF4B, RPS6 and EEF2K, and contributes to cell survival by repressing the pro-apoptotic function of BAD. Under conditions of nutrient depletion, the inactive form associates with the EIF3 translation initiation complex. Upon mitogenic stimulation, phosphorylation by the mammalian target of rapamycin complex 1 (mTORC1) leads to dissociation from the EIF3 complex and activation. The active form then phosphorylates and activates several substrates in the pre-initiation complex, including the EIF2B complex and the cap-binding complex component EIF4B. Also controls translation initiation by phosphorylating a negative regulator of EIF4A, PDCD4, targeting it for ubiquitination and subsequent proteolysis. Promotes initiation of the pioneer round of protein synthesis by phosphorylating POLDIP3/SKAR. In response to IGF1, activates translation elongation by phosphorylating EEF2 kinase (EEF2K), which leads to its inhibition and thus activation of EEF2. Also plays a role in feedback regulation of mTORC2 by mTORC1 by phosphorylating RICTOR, resulting in the inhibition of mTORC2 and AKT1 signaling. Mediates cell survival by phosphorylating the pro-apoptotic protein BAD and suppressing its pro-apoptotic function. Phosphorylates mitochondrial URI1 leading to dissociation of a URI1-PPP1CC complex. The free mitochondrial PPP1CC can then dephosphorylate RPS6KB1 at Thr-412, which is proposed to be a negative feedback mechanism for the RPS6KB1 anti-apoptotic function. Mediates TNF-alpha-induced insulin resistance by phosphorylating IRS1 at multiple serine residues, resulting in accelerated degradation of IRS1. In cells lacking functional TSC1-2 complex, constitutively phosphorylates and inhibits GSK3B. May be involved in cytoskeletal rearrangement through binding to neurabin. Phosphorylates and activates the pyrimidine biosynthesis enzyme CAD, downstream of MTOR.
p70 ribosomal S6 kinase (S6K) exists as two isoforms - S6K1 and S6K2 - which are activated by mitogenic stimuli such as growth factors, insulin and cytokines. In turn, p70 S6K phosphorylates the ribosomal protein S6. The S6K1 isoform also phosphorylates other proteins involved in the cell's translational machinery, including elF4B (initiation factor); eEF2K (elongation factor 2 kinase); and SKAR (RNA binding protein). As such, it is thought that S6K1 may be directly involved in cell growth and when considered alongside its position downstream of the PI3K and mTOR pathways, this activity makes S6K1 a potential target for cancer therapy.